ONEOK (NYSE:OKE) reported quarterly earnings of $0.92 per share which beat the analyst consensus estimate of $0.90 by 2.22 percent. This is a 19.48 percent increase over earnings of $0.77 per share from the same period last year.
FibroGen Stock Is Surging After The Bell: What’s Going On?
FibroGen shares are moving higher in Monday's after-hours session after the company announced the FDA cleared its Investigational New Drug (IND) FG-3165. The company also announced a new clinical trial supply agreement with Regeneron.
